TB treatment delays and associated risk factors in Dushanbe, Tajikistan, 2019-2021.

TB treatment delays and associated risk factors in Dushanbe, Tajikistan, 2019-2021.

Publication date: Dec 18, 2024

In Tajikistan, where there are about 8,000 cases annually, many new cases are being diagnosed with severe disease, indicating a delay in receiving care. We aimed to estimate the proportion with delayed care and the main factors contributing to delayed care. Using a retrospective cohort design, we conducted a study that included all people aged over 15 years who were newly diagnosed with pulmonary TB in Dushanbe from 2019 to 2021. We defined ‘patient delay’ as > 14 days from TB symptom onset to the first provider visit and ‘provider delay’ as > 3 days from the first visit to treatment initiation. Data was abstracted from medical records and participants were interviewed in-person. Multivariable negative binomial regression was used to estimate adjusted risk ratios (aRR) and 95% confidence intervals (CI). Of 472 participants, 49% were male, 65% had lung tissue cavitation, 33% had drug resistant TB, 11% had diabetes, 4% had HIV, and. Reported cases dropped from 196 in 2019 to 109 in 2020 and increased to 167 in 2021. The proportion of people experiencing patient delays was 82%, 72%, and 90% per year, respectively. The proportion of provider delays was 44%, 41% and 29% per year. Patient delay was associated with year (aRR: 1. 09 [CI:1. 02-1. 18] in 2021 vs. 2019), age (aRR:0. 91 [0. 82-0. 99] for 40-59-year-olds vs. 15-39-year-olds), having HIV (aRR:1. 22 [1. 08-1. 38]), having blood in sputum (aRR:1. 19 [1. 10-1. 28]), chest pain (aRR:1. 32 [1. 14-1. 54]), having at least two structural barriers vs. none (aRR:1. 52 [1. 28-1. 80]), having one of the following barriers: long wait lines (aRR:1. 36 [1. 03-1. 80]), feeling that healthcare services were expensive (aRR:1. 54 [1. 28-1. 85]), or having no time or too much work (aRR:1. 54 [1. 29-1. 84]). Provider delay was associated with year (aRR: 0. 67 [0. 51-0. 89] in 2021 vs. 2019), patients having to pay for X-ray services (aRR: 1. 59 [1. 22-2. 07]) and lacking direct-observed-therapy (DOTS) in facility (aRR: 1. 61 [1. 03-2. 52]). Patient delay was high before the COVID-19 pandemic and increased in 2021, while provider delay decreased during this time. Addressing structural barriers to healthcare services, such as increased DOTS facilities, expanded hours, and zero fees, may decrease delays.

Open Access PDF

Concepts Keywords
Diabetes Adolescent
Pandemic Adult
Therapy Aged
Antitubercular Agents
Antitubercular Agents
COVID-19
Female
HIV Infections
Humans
Male
Middle Aged
Patient delay
Retrospective Studies
Risk Factors
Tajikistan
Tajikistan
Time-to-Treatment
Treatment Delay
Tuberculosis
Tuberculosis, Multidrug-Resistant
Tuberculosis, Pulmonary
Young Adult

Semantics

Type Source Name
disease MESH treatment delays
disease IDO symptom
disease IDO blood
disease MESH chest pain
disease IDO facility
disease MESH COVID-19 pandemic
pathway REACTOME Reproduction
disease MESH Infectious Diseases
disease MESH Tuberculosis
pathway KEGG Tuberculosis
disease MESH community transmission
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH weight loss
disease IDO healthcare facility
disease MESH diabetes mellitus
disease MESH Marital status
disease MESH hepatitis
disease MESH Hypertension
disease IDO country
drug DRUGBANK Trestolone
disease IDO process
drug DRUGBANK Tretamine
drug DRUGBANK Dantron
drug DRUGBANK Etoperidone
disease MESH AIDS
disease MESH pulmonary tuberculosis
drug DRUGBANK Coenzyme M
disease MESH HIV Infections
disease MESH Tuberculosis Multidrug-Resistant

Original Article

(Visited 2 times, 1 visits today)